Autoantigens IA-2 and GAD in Type I (insulin-dependent) diabetes

Diabetologia

Volumn 42, Issue 1, 1999, Pages 3-14

  Leslie, R D G ^a   Atkinson, M A ^b   Notkins, A L ^c  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

Diabetes; GAD; IA 2; Immune response; Pathogenesis; Prediction

Indexed keywords

AUTOANTIGEN; GLUTAMATE DECARBOXYLASE; HLA DQ ANTIGEN; HLA DR ANTIGEN;

ANTIGEN DETECTION; AUTOIMMUNITY; CHROMOSOME 6; GENE LOCATION; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNOPATHOGENESIS; INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REVIEW;

ANIMALS; AUTOANTIBODIES; AUTOANTIGENS; DIABETES MELLITUS, TYPE 1; GLUTAMATE DECARBOXYLASE; HLA-DR ANTIGENS; HUMANS; MEMBRANE PROTEINS; PREDICTIVE VALUE OF TESTS; PROTEIN-TYROSINE-PHOSPHATASE; SENSITIVITY AND SPECIFICITY;

EID: 0032964798     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250051105     Document Type: Review

References (105)

1. 1. Atkinson MA, Maclaren NK (1994) The pathogenesis of insulin-dependent diabetes mellitus. N Engl Med J 331: 1428-1436
2. 2. Diabetes Epidemiology Research International Mortality Study Group (1991) Major cross-country differences in risk of dying for people with IDDM. Diabetes Care 14: 49-54
3. 3. La Porte RE, Matsushima M, Chang YF (1995) Prevalence and incidence of insulin-dependent diabetes. In: Harris MI et al. (eds) Diabetes in America, 2nd edn. NIH Publication No. 95-1468, Bethesda, pp 37-46
4. 4. Todd JA (1995) Genetic analysis of type 1 diabetes using whole genome approaches. Proc Natl Aca Sci USA 92: 8560-8565
5. 5. Leslie RDG, Elliott RB (1994) Early environmental events as a cause of IDDM. Evidence and implications. Diabetes 43: 843-850
6. 6. Dahlquist G (1993) Etiological aspects of insulin dependent diabetes mellitus: an epidemiological perspective. Autoimmunity 15: 61-65
7. 7. Foulis AK, Stewart JA (1984) The pancreas in recent-on-set Type 1 (insulin-dependent) diabetes mellitus: insulin content of islets, insulitis and associated changes in the exocrine acinar tissue. Diabetologia 26: 456-461
8. 8. Itoh N, Hanafusa T, Miyazaki A et al. (1993) Mononuclear cell infiltration and its relation to the expression of major histocompatibility complex antigens and adhesion molecules in pancreas biopsy specimens from newly diagnosed insulin-dependent diabetes mellitus patients. J Clin Invest 92: 2313-2322
9. 9. Conrad B, Weidmann E, Trucco G et al. (1994) Evidence for superantigen involvement in insulin-dependent diabetes mellitus aetiology. Nature 371: 351-355
10. 10. Tun RYM, Peakman M, Alviggi L et al. (1994) Importance of persistent cellular and humoral immunechanges before diabetes develops: prospective study of identical twins. BMJ 308: 1063-1068
11. 11. Eisenbarth GS, Verge CF, Allen H, Rewers MJ (1993) The design of trials for prevention of IDDM. Diabetes 42: 941-947
12. 12. Rossini AA, Handler ES, Mordes JP, Greiner DL (1995) Human autoimmune diabetes mellitus: lessons from BB rats and NOD mice-Caveat emptor. Clin Immunol Immunopathol 74: 2-9
13. 13. Tisch R, McDevitt H (1996) Insulin-dependent diabetes mellitus. Cell 85: 291-297
14. 14. Hawa M, Rowe R, Lan MS et al. (1997) Value of antibodies to islet protein tyrosine phosphatase-like molecule in predicting Type 1 diabetes. Diabetes 48: 1270-1275
15. 15. Verge CF, Gianani R, Kawasaki E et al. (1996) Predicition of type 1 diabetes in first-degree relatives using a combination of insulin, GAD and ICA512bdc/IA-2 autoantibodies. Diabetes 45: 926-933
16. 16. Lan MS, Lu J, Goto Y, Notkins AL (1994) Molecular cloning and identification of a receptor-type protein tyrosine phosphatase, IA-2, from human insulinoma. DNA and Cell Biology 13: 505-514
17. 17. Lan MS, Wasserfall C, MacLaren NK, Notkins AL (1996) IA-2, a transmembrane protein of the protein tyrosine phosphatase family, is a major autoantigen in insulin-dependent diabetes mellitus. Proc Natl Acad Sci USA 93: 6367-6370
18. 18. Magistrelli G, Toma S, Isacchi A (1996) Substitution of two variant residues in the protein tyrosine phosphatase-like PTP35/IA-2 sequence reconstitutes catalytic activity. Biochem Biophys Res Commun 227: 581-588
19. 19. Solimena M, Dirkx RJ, Hermel JM et al. (1996) ICA 512, an autoantigen of type 1 diabetes, is an intrinsic membrane protein of neurosecretory granules. EMBO J 15: 2102-2114
20. 20. Xie H, Notkins AL, Lan MS (1996) IA-2, a transmembrane protein tyrosine phosphatase, is expressed in human lung cancer cell lines with neuroendocrine phenotype. Cancer Res 56: 2742-2744
21. 21. Christie MR, Hollands JA, Brown TJ, Michelsen BK, Delovitch TL (1993) Detection of pancreatic islet 64,000 M(r) autoantigens in insulin-dependent diabetes distinct from glutamate decarboxylase. J Clin Invest 92: 240-248
22. 22. Xie H, Deng JY, Notkins AL, Lan ML (1988) Expression, characterisation, processing and immunogenicity of an insulin-dependent diabetes mellitus autoantigen, IA-2, in SF-9 cells. J Clin Exp Immunol
23. 23. Lu J, Li Q, Xie H et al. (1996) Identification of a second transmembrane protein tyrosine phosphatase, IA-2β, as an autoantigen in insulin-dependent diabetes mellitus: precursor of the 37 kDa tryptic fragment. Proc Natl Acad Sci USA 93: 2307-2311
24. 24. Xie H, Zhang B, Matsumoto Y, Li Q, Notkins AL, Lan MS (1997) Autoantibodies to IA-2 and IA-β in insulin-dependent diabetes mellitus recognize conformational epitopes: location of the 37 and 40 kDa fragments determined. J Immunol 159: 3662-3667
25. 25. Payton MA, Hawkes CJ, Christie MR (1995) Relationship of the 37,000-and 40,000-Mr tryptic fragments of islet antigens in insulin-dependent diabetes to the protein tyrosine phosphatase-like molecule IA-2 (ICA512). J Clin Invest 96: 1506-1511
26. 26. Lampasona V, Bearzatto M, Genovese S, Bosi E, Ferrari M, Bonifacio E (1996) Autoantibodies in insulin-dependent diabetes recognize distinct cytoplasmic domains of the protein tyrosine phosphatase-like IA-2 autoantigen. J Immunol 157: 2707-2711
27. 27. Rabin DU, Pleasic SM, Shapiro JA et al. (1994) Islet cell antigen 512 is a diabetes-specific islet autoantigen related to protein tyrosine phosphatases. J Immunol 152: 3183-3188
28. 28. Zhang BW, Lan MS, Notkins AL (1997) Autoantibodies to IA-2 in IDDM: location of major antigenic determinants. Diabetes 46: 40-43
29. 29. Bingley PJ, Bonifacio E, Williams AJK, Genovese S, Bottazzo GF, Gale EAM (1997) Prediction of IDDM in the general population: strategies based on combination of autoantibody markers. Diabetes 46: 1701-1710
30. 30. Seissler J, Morgenthaler NG, Achenback P et al. (1996) Combined screening for autoantibodies to IA-2 and antibodies to glutamic acid decarboxylase in first degree relatives of patients with IDDM. Diabetolgia 39: 1351-1356
31. 31. Gorus KF, Goubert P, Semakula C et al. (1997) IA-2 autoantibodies complement GAD65 autoantibodies in new-onset IDDM patients and help predict impending diabetes in their siblings. Diabetologia 40: 95-99
32. 32. Genovese S, Bonfanti R, Bazzigaluppi E et al. (1996) Association of IA-2 autoantibodies with HLS DR4 phenotypes in IDDM. Diabetologia 39: 1223-1226
33. 33. Lohmann T, Seissler J, Verlohren H-J et al. (1997) Distinct genetic and immunological features in patients with onset of IDDM before and after age 40. Diabetes Care 20: 524-529
34. 34. Leslie RDG, Pozzilli P (1994) Type I diabetes masquerading as Type II diabetes. Diabetes Care 17: 1214-1219
35. 35. Niskanen LK, Tuomi T, Karjalainen J, Groop LC, Uusitupa MIJ (1995) GAD antibodies in NIDDM: ten year follow up from the diagnosis. Diabetes Care 18: 1557-1565
36. 36. Tuomi T, Groop LC, Zimmet PZ, Rowley MJ, Knowles W, Mackay IR (1993) Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of diabetes. Diabetes 42: 359-362
37. 37. Elbein SC, Wegner K, Miles C, Yu L, Eisenbarth G (1997) The role of late-onset autoimmune diabetes in white familial NIDDM pedigrees. Diabetes Care 20: 1248-1251
38. 38. Seissler J, de Sonnaville JJJ, Morgenthaler NG et al. (1988) Immunological heterogeneity in Type I diabetes: presence of distinct autoantibody patterns in patients with acute onset and slowly progressive disease. Diabetologia 41: 891-897
39. 39. Turner R, Stratton I, Horton V et al. (1997) UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. Lancet 350: 1288-1293
40. 40. Durinovic-Bello I, Hummel M, Ziegler AG (1996) Cellular immune response to diverse islet cell antigens in IDDM. Diabetes 45: 795-800
41. 41. Ellis TM, Schatz D, Lan MS et al. (1998) The relationship between humoral and cellular immunity to IA-2 in IDDM. Diabetes 47: 566-569
42. 42. Honeyman MC, Stone NL, Harrison LC (1998) T-cell epitopes in Type I diabetes autoantigen tyrosine phosphatase IA-2: potential for mimicry with rotavirus and other environmental agents. Mol Med 4: 231-239
43. 43. Notkins AL, Zhang B, Matsumoto Y, Lan MS (1997) Comparison of IA-2 and IA-β and with six other members of the protein tyrosine phosphatase family: recognition of antigenic determinants by IDDM sera. J Autoimmunity 10: 245-250
44. 44. Li Q, Borovitskaya AE, DeSilva MG et al. (1997) Autoantigens in insulin-dependent diabetes mellitus: molecular clonging and characterization of human IA-2β. Proc Assoc Am Physicians 109: 429-439
45. 45. Wasmeier C, Hutton JC (1996) Molecular cloning of phogrin, a protein-tyrosine phosphatase homologue localized to insulin secretory granule membranes. J Biol Chem 271: 18161-18170
46. 46. Cui L, Yu WP, DeAizpurua HJ, Schmidli RS, Pallen CJ (1996) Cloning and characterisation of islet cell antigen-related protein-tyrosine phosphatase (PTP), a novel receptor-like PTP and autoantigen in insulin-dependent diabetes. J Biol Chem 271: 24817-24823
47. 47. Smith PD, Barker KT, Wang J, Lu YJ, Shipley J, Crompton MA (1996) ICAAR, a novel member of a new family of transmembrane, tyrosine phosphatase-like proteins. Biochem Biophys Res Commun 229: 402-411
48. 48. Fitzgerald LR, Walton KM, Dixon JE, Largent BL (1997) PTP NE-6: a brain-enriched receptor-type protein tyrosine phosphatase with a divergent catalytic domain. J Neurochem 68: 1820-1829
49. 49. Ellis TM, Atkinson MA (1996) The clinical significance of an autoimmune response against glutamic acid decarboxylase. Nature Med 2: 148-153
50. 50. Karlsen AE, Hagopian WA, Petersen JS et al. (1991) Cloning and primary structure of a human iselt isoform of glutamic acid decarboxylase from chromosome 10. Proc Natl Acad Sci USA 88: 8337-8341
51. 51. Blu D-F, Erlander MG, Hitz BC et al. (1992) Two human glutamate decarboxylases, 65-kD GAD and 67-kD GAD, are each encoded by a single gene. Proc Natl Acad Sci USA 89: 2115-2119
52. 52. Christgau S, Aanstoot HJ, Schierbeck H et al. (1992) Membrane anchoring of the autoantigen GAD65 to microvessicles in pancreatic beta-cells by palmitoylation in the NH2-terminal domain. J Cell Biol 118: 309-320
53. 53. Baekkeskov S, Nielsen JH, Marner B, Bilde T, Ludvigsson J, Lernmark A (1982) Autoantibodies in newly-diagnosed diabetic children immunoprecipitate pancreatic islet cell proteins. Nature 298: 167-169
54. 54. Baekkeskov S, Aanstoot HJ, Chistgau S et al. (1990) The 64-kD autoantigen in insulin-dependent diabetes is the GABA-synthesizing enzyme glumatic acid decarboxylase. Nature 347: 151-156
55. 55. Kaufman D, Erlander MG, Clare-Salzler M et al. (1992) Autoimmunity to two forms of glutamate decarboxylase in insulin dependent diabetes mellitus. J Clin Invest 89: 283-292
56. 56. Butler MH, Solimena M, Dirkz RJ, Hayday A, DeCamilli P (1993) Identification of a dominant epitope of glutamic acid decarboxylase (GAD65) recognized by autoantibodies in stiff man syndrome. J Exp Med 178: 2097-2106
57. 57. Kim J, Namchuk M, Bugawan T et al. (1994) Higher autoantibody levels and recognition of a linear NH2-terminal epitope in the autoantigen GAD65, distinguish stiffman syndrome from insulin-dependent diabetes mellitus. J Exp Med 180: 595-606
58. 58. Daw K, Ujihara N, Atkinson MA, Powers AC (1996) Glutamic acid decarboxylase autoantibodies in stiff man syndrome and insulin-dependent diabetes mellitus exhibit similarities and differences in epitope recognition. J Immunol 156: 818-825
59. 59. Richter W, Shi Y, Baekkeskov S (1993) Autoreactive epitopes defined by diabetes-associated human monoclonal antibodies are localized in the middle and C-terminal domains of the smaller form of glutamate decarboxylase. Pro Natl Acad Sci USA 90
60. 60. Schmidli RS, Colman PG, Bonifacio E et al. (1994) High level of concordance between assays for glutamine acid decarboxylase antibodies. The First International Glutamic Acid Decarboxylase Antibody Workshop. Diabetes 43: 1005-1009
61. 61. Schmidli RS, Colman PG, Bonifacio E (1995) Disease sensitivity and specificity of 52 assays for glutamic acid decarboxylase antibodies. The Second International GADAB Workshop. Diabetes 44: 636-640
62. 62. Harrison LC, Honeymoon MC, DeAizpurua HJ et al. (1993) Inverse relation between humoral and cellular immunity to glutamic acid decarboxylase in subjects at risk of insulin-dependent diabetes. Lancet 341: 1365-1369
63. 63. Vandenvalle CL, Falorni A, Svanhohn S, Lermark A, Pipeleers PG, Gonis FK (1995) High diagnostic sensitivity of glutamate decarboxylase autoantibodies in insulin-dependent diabetes mellitus with clinical onset between age 20 and 40 years. The Belgian Diabetes Registry. J Clin Endocrinol Metab 80: 846-851
64. 64. Schmidli RS, DeAizpurua HJ, Harrison LC, Colman PG (1994) Antibodies to glutamic acid decarboxylase in at-risk and clinical insulin-dependent diabetic subjects: relationship to age, sex and islet cell antibody status, and temporal profile. J Autoimmun 7: 55-66
65. 65. Hagopian W, Michelsen B, Karlsen A et al. (1993) Autoantibodies in IDDM primarily recognize the 65,000-Mr rather than the 67,000-Mr isoform of glutamic acid decarboxylase. Diabetes 42: 631-636
66. 66. Velloso LA, Kampe O, Hallberg A, Christmanson L, Betsholtz C, Karlson GA (1993) Demonstration of GAD-65 as the main immunogenic isoform of glutamate decarboxylase in type I diabetes and determination of autoantibodies using a radioligand produced by eukaryotic expression. J Clin Invest 91: 2084-2090
67. 67. Atkinson MA, Kaufman DL, Newman D, Tobin AJ, Maclaren NK (1993) Islet cell cytoplasmic autoantibody reactivity to glutamate decarboxylase in insulin-dependent diabetes. J Clin Invest 91: 350-356
68. 68. Gottsater A, Landin-Olsson M, Fernlund P, Lernmark A, Sundkvist G (1993) β-cell function in relation to islet cell antibodies during the first 3 years after clinical diagnosis of diabetes in type II diabetic patient. Diabetes Care 16: 902
69. 69. Zimmet PZ, Tuomi T, Mackay IR et al. (1990) Latent autoimmune diabetes mellitus in adults (LADA): the role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency. Diabet Med 11: 299-303
70. 70. Tuomilehto J, Zimmet P, Mackay IR et al. (1994) Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease. Lancet 343: 1383-1385
71. 71. Atkinson MA, Kaufman DL, Campbell L et al. (1992) Peripheral blood mononuclear cells respond to glutamate decarboxylase in insulin dependent diabetes. Lancet 339: 548-549
72. 72. Honeymoon MC, Cram DS, Harrison LC (1993) Glutamic acid decarboxylase 67-reactive T cells: a marker of insulin-dependent diabetes. J Exp Med 177: 535-540
73. 73. Atkinson MA, Bowman MA, Campbell L, Darrow BL, Kaufman DL, Maclaren NK (1994) Cellular immunity to a determinant common to glutamate decarboxylase and coxsackie virus in insulin-dependent diabetes. J Clin Invest 94,5: 2125-2129
74. 74. Lohmann T, Leslie RDG, Hawa M, Geysen M, Rodda S, Londei M (1994) Immunodominant epitopes of glutamic acid decarboxylase 65 and 67 in insulin-dependent diabetes mellitus. Lancet 343: 1607-1608
75. 75. Zechel M, Elliott JF, Atkinson MA, Singh B (1998) Characterization of novel T-cell epitopes on 65 kDa and 67 kDa glumatic acid decarboxylase relevant in autoimmune reponses in NOD mice. J Autoimmune 11: 83-95
76. 76. Kaufman DL, Clare-Salzler MC, Sercarz EE, Tobin AJ, Atkinson MA, Lehmann P (1993) Spontaneous loss of self tolerance to glutamate decarboxylase is a key event in the pathogenesis of murine insulin-dependent diabetes. Nature 366: 69-71
77. 77. Tisch R, Yang X-D, Singer SM, Liblau RS, Fugger L, McDevitt HO (1993) Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice. Nature 366: 72-75
78. 78. Zekzer D, Wong S, Ayalon O et al. (1998) GAD-reactive CD4 + Th1 cells induce diabetes in NOD/SCID mice. J Clin Invest 101: 68-73
79. 79. Tian J, Clare-Salzer MC, Hershenfeld A et al. (1996) Modulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes-prone mice. Nat Med 2: 1348-1353
80. 80. Endl J, Otto H, Jung G et al. (1997) Identification of naturally processed T cell epitopes from glutamic acid decarboxylase presented in the context of HLA-DR alleles by T lymphocytes of recent onset IDDM patients. J Clin Invest 99: 2405-2415
81. 81. Patel SD, Cope AP, Congia M et al. (1997) Identification of immunodominant T cell epitopes of human glutamic acid decarboxylase 65 by using HLA-DR (α*0101, β1*0401) transgenic mice. Proc Natl Acad Sci USA 94: 8082-8087
82. 82. Wicker LS, Chen SL, Nepom GT et al. (1996) Naturally processed T cell epitopes from human glutamic acid decarboxylase identified using mice transgenic for the type 1 diabetes-associated human MHC class I allele. J Clin Invest 98: 2597-2603
83. 83. Lampeter EF, Seifert I, Lohmann D et al. (1994) Inflammatory islet damage in patients bearing HLA-DR3 and/or DR4 halotypes does not lead to islet autoimmunity. Diabetologia 37: 471-475
84. 84. Ma SW, Zhao KL, Yin ZQ et al. (1997) Transgenic plants expressing autoantigens fed to mice to induce oral immune tolerance. Nature Med 3: 793-796
85. 85. Elliott JF, Quill HY, Bhatti S et al. (1994) Immunization with the larger isoform of mouse glutamic acid decarboxylase (GAD 67) prevents autoimmune diabetes in NOD mice. Diabetes 43: 1494-1499
86. 86. Petersen JS, Karlsen AE, Markholst W, Worsaae A, Dyrberg T, Michelsen B (1994) Neonatal tolerization with glutamic acid decarboxylase but not with bovine serum albumin delays the onset of diabetes in nonobese diabetic mice. Diabetes 43: 1478-1484
87. 87. Blanas E, Carbone FR, Allismi J, Miller JF, Heath WR (1996) Induction of autoimmune diabetes by oral administration of autoantigen. Science 274: 1707-1709
88. 88. McFarland HF (1996) Complexities in the treatment of autoimmune disease. Science 274: 2037-2038
89. 89. Bellmann K, Kolb H, Rastegar S, Jee P, Scott FW (1998) Potential risk of oral insulin with adjuvant for the prevention of Type I diabetes: a protocol effective in NOD mice may exacerbate disease in BB rats. Diabetologia 41: 844-847
90. 90. Bonifacio E, Genovese S, Braghi S et al. (1995) Islet autoantibody markers in IDDM: risk assessment strategies yielding high sensitivity. Diabetologia 38: 816-822
91. 91. Bingley PJ, Bonifacio E, Gale EAM (1993) Can we really predict IDDM? Diabetes 42: 213-220
92. 92. Weist-Ladenburgher U, Hartmann R, Hartmann U, Berling K, Bohm BO, Richter W (1997) Combined analysis and single-step detection of GAD65 and IA2 autoantibodies in IDDM can replace the histochemical islet cell antibody test. Diabetes 46: 565-571
93. 93. Dobersen MJ, Bell AM, Jenson AB, Notkins AL, Ginsberg-Fellner F (1979) Detection of antibodies to islet cells and insulin with paraffin-embedded pancreas as antigen. Lancet II:1078
94. 94. Kulmala P, Savola K, Petersen JS et al. (1998) Prediction of insulin-dependent-diabetes mellitus in siblings of children with diabetes: a population based study. J Clin Invest 101: 327-336
95. 95. Seissler J, Morgenthaler NG, Achenbach P et al. (1996) Combined screening for autoantibodies to IA-2 and antibodies to glumatic acid decarboxylase in first degree relatives of patients with IDDM. Diabetologia 39: 1351-1356
96. 96. Christie MR, Roll U, Payton MA, Hatfield ECI, Ziegler A-G (1997) Validity of screening for individuals at risk for Type I diabetes by combined analysis of antibodies to recombinant proteins. Diabetes Care 20: 965-970
97. 97. Bingley PJ, Christie MR, Bontanti R et al. (1994) Combined analysis of autoantibodies enhances prediction of IDDM in islet cell antibody (ICA) positive relatives. Diabetes 43: 1304-1310
98. 98. Zimmet PZ, Elliott RB, Mackay IR et al. (1994) Autoantibodies to glutamic acid decarboxylase and insulin in islet cell antibody positive presymptomatic type I diabetes mellitus: frequency and segregation by age and gender. Diabet Med 11: 866-871
99. 99. Feeney SJ, Myers MA, Mackay IR et al. (1997) Evaluation of ICA512Ax in combination with other islet cell autoantibodies at the onset of IDDM. Diabetes Care 20: 1403-1407
100. 100. Dittler J, Seidel D, Schenker M, Ziegler AG (1998) GADIA2-combi determination as first-line screening for improved prediction of type I diabetes in relatives. Diabetes 47: 592-597
101. 101. Yokota I, Matsuda J, Naito E, Ito M, Shima K, Kuroda Y (1998) Comparison of GAD and ICA512/IA-2 antibodies at and after the onset of IDDM. Diabetes Care 21: 49-52
102. 102. Thai AC, Eisenbarth GS (1993) Natural history of IDDM. Diabetes Rev 123: 37-64
103. 103. Roll U, Christie MR, Fuchtenbusch M, Payton M, Hawkes CJ, Ziegler A-G (1996) Perinatal autoimmunity in offspring of diabetic parents. Diabetes 45: 967-973
104. 104. Savola K, Bonifacio E, Sabbah E et al. (1998) IA-2 antibodies - a sensitive marker of IDDM with clinical onset in childhood and adolescence. Diabetologia 41: 424-429
105. 105. Tian J, Atkinson MA, Clare-Salzer M et al. (1996) Nasal administration of glutamate decarboxylase (GAD 65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes. J Exp Med 183: 1561-1567